Description

The US is the largest healthcare market in the world and where we see the greatest opportunity.

We intend to leverage our platform technologies dCELL® and BioRinse to further our market penetration through a hybrid sales model, a combination of direct sales, distribution and OEM agreements.

2018 Performance

  • Significant OEM agreement signed with Arthrex for the BioRinse portfolio in the US market
  • Extension to the Premier, Inc. GPO Agreement
  • "Supplier Horizon Award" achievement from GPO, Vizient, Inc.
  • Uptake by prestigious US establishments such as the Cleveland Clinic

Focus and Goals for 2019

Scale:

  • Focus on higher volume accounts
  • SurgiPure® XD US launch
  • Expand partners for specific fields of use and OEM
  • New Product Development related to market opportunities
  • Expand Group Purchasing Organisation coverage
  • Expand commercial scale
  • Expand portfolio penetration in existing accounts

Description

At the beginning of 2018 we revised our commercial strategy with a focus on establishing and building strategic partnerships to further our market access and penetration

This also allows for the potential to increase OEM agreements and initiate discussions around joint IP collaborations.

2018 Performance

  • Distribution agreement signed with ARMS Medical for the use of DermaPure® in urogynaecology procedures
  • Distribution agreement signed with Pennine Healthcare for the UK distribution of BioRinse products into the spine market
  • Arthrex extension into other EU markets for sports medicine applications

Focus and Goals for 2019

Continue to refocus:

  • Tissue Regenix Group will work in conjunction with partners’ R&D teams
  • Additional regions identified to broaden geographic reach
  • Development programmes underway with key industry players

Description

Our success is reliant upon the ability to commercialise our current portfolio and the potential for augmenting this with line extensions and new innovative products.

We therefore look to establish a database of compelling real world clinical data to validate our technology platforms and further our physician conversion rates.

These clinical data portfolios are also imperative when we seek new strategic partnership opportunities and when navigating regulatory clearance in new territories.

2018 Performance

  • Two year clinical data collection for OrthoPure XT
  • CE mark application for OrthoPure XT submitted
  • New product development "stage and gate" process implemented
  • DermaPure® post marketing study protocol for the collection of real world clinical data developed

Focus and Goals for 2019

Data: drive decision makers through empirical data:

  • Commencement of DermaPure® post marketing trial
  • Prospective clinical and health economic studies
  • Two year clinical data collected for OrthoPure XT, will continue to five years
  • Product line extension potential to augment product portfolio and an expedited route to market
  • Increase speed at which products are brought to market
  • Strengthen R&D capabilities

Description

Our current commercialization efforts are focused on the US markets; however, there is the opportunity and market demand for us to enter new territories.

2018 Performance

  • Extension of the Arthrex partnership to bring the BioRinse portfolio into the UK and EU.
  • Distribution agreement signed for the spine market in the UK.

Focus and Goals for 2019

Europe

  • Extend Human Tissue portfolio opportunities via Arthrex EU Agreement
  • Launch OrthoPure XT (Porcine Tendon)

China

  • Ongoing discussion for licencing and distribution opportunities

Latin America

  • Working towards distribution agreements in several countries for BioRinse products.

You may also be interested in